IntoDNA is taking a bigger step into translational oncology diagnostics at the 2026 American Association for Cancer Research Annual Meeting with poster data on two new assays, sSTRIDE-NER and sSTRIDE-PARP1, both built on its STRIDE platform for direct measurement of DNA damage and repair biology at single-cell resolution. The Kraków-based precision medicine company says the assays are designed to functionally measure nucleotide excision repair activity and PARP1 trapping at single-strand DNA breaks, two capabilities that could matter for drug development, biomarker discovery, and patient stratification in DNA damage response-driven oncology.
Why direct measurement of DNA repair activity could matter more than another biomarker layer in oncology
The central commercial and scientific pitch behind intoDNA’s AACR 2026 posters is that oncology still lacks robust functional assays that show what DNA repair machinery is actually doing inside cells and tissue samples, rather than inferring that activity through indirect surrogate markers. That distinction sounds technical, but it is exactly where many translational programs either become more precise or quietly fall apart.
The first poster, scheduled for April 20 in the Experimental and Molecular Therapeutics track, focuses on sSTRIDE-NER, an assay intended to directly measure nucleotide excision repair activity. IntoDNA says the assay produced minimal background signal in negative controls and showed a time-dependent increase in nuclear signal intensity, which the company interprets as consistent with accumulation of nucleotide excision repair-associated single-strand breaks. In practical terms, that positions the assay as a tool for probing how tumors handle DNA lesions of the kind associated with platinum chemotherapy and other DNA-damaging interventions.
That matters because nucleotide excision repair has long been relevant to resistance biology, especially in settings where platinum sensitivity and acquired resistance can dramatically alter treatment value. The problem is that many existing approaches to repair profiling rely on genomic proxies, transcript levels, or downstream signaling markers, which do not always map neatly onto functional repair capacity in living tumor cells. A direct assay that can visualize and quantify activity in situ would therefore be attractive not just as a lab tool, but as a potential bridge between mechanism and clinical decision-making.
The opportunity, however, should not be overstated. Poster-stage evidence is useful for visibility and scientific discussion, but it is still early. Functional assays often look compelling in controlled systems before they run into the messier realities of heterogeneous tumors, variable sample quality, preanalytical handling, and the need for reproducible cutoffs across laboratories. The leap from elegant translational assay to widely trusted clinical biomarker is usually much larger than companies initially suggest.
How the PARP1 trapping assay could sharpen competition in an already crowded DNA damage response field
The second AACR poster, scheduled for April 22 in a late-breaking Experimental and Molecular Therapeutics session, may be the more commercially provocative of the two. IntoDNA says sSTRIDE-PARP1 directly detects PARP1 localized at single-strand DNA breaks at single-cell resolution and enables a quantitative, functional measurement of PARP1 engagement and trapping in intact cells. The company also says the assay can distinguish between cell lines with different basal levels of PARylation and PARP1 activity.
That matters because PARP biology is no longer a niche research theme. It sits at the center of a mature and still strategically important class of oncology therapeutics, where differences in trapping potency, target engagement, resistance patterns, and combination tolerability continue to influence development strategy. A platform that can directly compare how different PARP inhibitors engage damaged DNA could become useful well beyond basic pharmacology. It could help preclinical teams compare molecules, help translational groups study why some tumors stop responding, and potentially help developers think more precisely about patient enrichment.
This is where intoDNA’s positioning becomes more interesting. The company is not trying to compete as a drug developer. It is trying to sell infrastructure for decision-making in a field where better functional readouts can reduce uncertainty. If that works, the value proposition is not limited to one assay or one cancer type. It extends across biomarker development, mechanism-of-action studies, combination design, and perhaps eventually response monitoring in selected clinical settings.
Still, the risks here are just as clear. The PARP inhibitor field is already full of well-developed translational frameworks, and labs working in DNA damage response biology are not short of assays. IntoDNA therefore has to prove not merely that sSTRIDE-PARP1 works, but that it provides information others do not, or provides familiar information with meaningfully better specificity, sensitivity, spatial context, or operational practicality. Novelty alone is not enough. It needs to change a decision.
Why AACR visibility helps, but why assay companies still need a much harder validation story afterward
Being accepted for poster presentations at AACR gives intoDNA scientific visibility at one of the year’s most important cancer research meetings, held in San Diego from April 17 to April 22, 2026. For an assay and diagnostics-focused company, that visibility matters because AACR is often where early translational tools begin shaping the conversations that later influence partnerships, validation studies, and development collaborations.
The late-breaking placement of the PARP1 poster may also help the company draw attention, especially in a research environment where functional biomarkers and DNA damage response targeting remain active areas of investment. But conference visibility should not be confused with clinical traction. Many technologies earn scientific interest at AACR. Far fewer become embedded in trial protocols, companion diagnostic pathways, or standard translational workflows.
That is the real challenge ahead for intoDNA. Its STRIDE platform is described by the company as a direct and sensitive way to detect DNA ends in situ, with single-cell resolution and AI-enabled quantification. On paper, that is a strong translational pitch because it combines spatial context, mechanistic proximity, and quantitative output. In practice, adoption will depend on whether biopharma partners and clinical researchers can integrate the assays into real-world workflows without excessive complexity, turnaround burden, or interpretive ambiguity.
The market has learned this lesson repeatedly. Biomarker technologies often promise to reduce uncertainty, but unless they fit into drug development timelines and clinical research operations, they remain scientifically admired but commercially peripheral. IntoDNA will need not just more datasets, but evidence that these assays are reproducible across sites, robust in patient-derived material, and tied to outcomes that matter to sponsors and clinicians.
What sSTRIDE-NER and sSTRIDE-PARP1 may reveal about the next wave of biomarker competition in precision oncology
What intoDNA is really signaling through these posters is a broader thesis about where precision oncology may be headed next. The first generation of biomarker strategies leaned heavily on mutations, expression patterns, and static molecular classification. Those approaches remain essential, but they often leave an unresolved gap between molecular identity and functional behavior. DNA repair is one of the clearest examples of that gap.
A tumor may carry genomic features associated with repair deficiency or therapy response, yet still behave differently in treatment because repair activity is dynamic, context-dependent, and shaped by prior exposure and adaptive resistance. Functional assays that can show what is happening inside cells at the moment of testing could therefore become more important as oncology moves toward finer treatment matching.
That is why the two assays should be read together. sSTRIDE-NER is aimed at a repair pathway relevant to platinum response and broader resistance biology. sSTRIDE-PARP1 is aimed at a pathway already deeply tied to drug mechanism and class differentiation. Together, they suggest that intoDNA wants to build a portfolio of functional DNA damage response readouts that can serve as translational tools rather than one-off scientific curiosities.
The upside is obvious. If the company can systematically extend STRIDE-derived assays across DNA damage response biology, it could become a specialized platform partner for oncology drug developers that need better pharmacodynamic and biomarker tools. The limitation is equally obvious. Platform stories become credible only when they show repeatable utility across multiple contexts, not just elegant posters and mechanistic claims.
Why the company’s next test is not scientific visibility, but whether drug developers can act on the data
For industry watchers, the most important question is no longer whether intoDNA can generate interesting data. It is whether sponsors can use those data to make better choices. That is the threshold that separates a compelling diagnostics narrative from a durable translational business.
If sSTRIDE-NER can help identify functionally distinct nucleotide excision repair states in tumor models and patient samples, developers may see value in using it to study platinum sensitivity, resistance emergence, or combinations involving DNA repair-targeting agents. If sSTRIDE-PARP1 can reliably distinguish trapping behavior and functional target engagement across compounds and samples, it may find a place in comparative profiling, resistance work, and trial biomarker research. But those use cases will require outcome-linked validation, not just mechanistic plausibility.
Clinicians and translational scientists are likely to watch for three things next. First, can the assays generate consistent data in heterogeneous clinical specimens rather than selected cell systems. Second, can assay readouts be correlated with treatment response, resistance, or drug exposure in a way that alters development or care decisions. Third, can the platform be operationalized at the speed and rigor required by biopharma programs.
IntoDNA’s AACR 2026 presence therefore looks less like a conventional conference update and more like an early test of whether functional DNA repair diagnostics can claim a larger role in precision oncology’s next chapter. The science is interesting, the strategic angle is credible, and the translational ambition is clear. The harder part begins after the posters come down.
IntoDNA unveils sSTRIDE-NER and sSTRIDE-PARP1 at AACR 2026, can functional DNA repair assays reshape precision oncology? added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →